Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rheumatoid Arthritis Clear all
Recruiting Phase 1 Interventional

A Study of AZD0120 in Autoimmune Diseases

NCT07295847
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

NCT02638948
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986142, Placebo, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Huntsville, Alabama • Fullerton, California • Hemet, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 21, 2026, 10:04 AM EDT
Withdrawn No phase listed Observational

Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement

NCT00589485
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Knee Arthritis
Interventions
Simplex® Bone Cement, Cobalt™ Bone Cement
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Warsaw, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 2Phase 3 Interventional

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

NCT00042406
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Humax-CD4, Placebo
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis

NCT00055133
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Micellar Paclitaxel for Injection
Drug
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00233558
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab (up to 9 months exposure), methotrexate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Jul 21, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114
View directory record Official record
Conditions
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

NCT02784106
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activity, Rheumatoid and Osteoarthritis, and Weight Management

NCT00365404
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis
Interventions
Diet and exercise promotion
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

NCT05363891
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Natrunix, Placebo
Drug
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Covina, California • Encino, California • Rancho Mirage, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Completed No phase listed Observational

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

NCT01698515
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Jul 21, 2026, 10:04 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jul 21, 2026, 10:04 AM EDT
Completed No phase listed Observational

Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository

NCT01070121
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 21, 2026, 10:04 AM EDT
Enrolling by invitation No phase listed Observational

Comprehensive Reverse Shoulder Data Collection

NCT03404778
View directory record Official record
Conditions
Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthitis
Interventions
Biomet Comprehensive Reverse Shoulder
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2036
U.S. locations
4
States / cities
Towson, Maryland • Royal Oak, Michigan • Edina, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00425321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

NCT00280917
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CF101
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Peoria, Arizona • Albany, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

NCT00427804
View directory record Official record
Conditions
Rheumatoid Arthritis, Crohn's Disease
Interventions
calcitriol
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 50 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 21, 2026, 10:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

NCT00001852
View directory record Official record
Conditions
Lymphoma, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
4 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 10:04 AM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 21, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 21, 2026, 10:04 AM EDT